Aspire Biopharma Holdings, Inc.
ASBPHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Aspire Biopharma Holdings, Inc. (ASBP) is listed under Biotechnology. With a market capitalization of $12.4M, it sits in micro-cap territory. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management.
Market Cap
$12.4M
Beta
0.17
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-6.65
EPS (Fwd)
—
ROE
-1032.1%
ROA
60.6%
Cash
$12.2M
Total Debt
$0
Free CF
$7.4M
52W Change
-48.5%
Annual Financials
Cash vs Debt
Where ASBP stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ASBP finished 131.99% above its 150-day moving average ($3.97) and 136.76% above its 200-day moving average ($3.89). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ASBP overbought or oversold?
At the September 3, 2026 close, ASBP's RSI(14) was 82.0, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Aspire Biopharma Holdings, Inc. reports $12.2M in cash and $0 in total debt. The company generates $7.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -1032.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 60.6% further supports the picture of efficient asset utilization.
ASBP's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Aspire Biopharma Holdings, Inc.'s trajectory.